GGD Amsterdam participates in the large international PrEP-study DISCOVER. This study is to establish the safety and effectiveness of the new pill F/TAF in comparison to the existing PrEP pill Truvada. You can apply until the 26th of March.
About the DISCOVER-study
The DISCOVER-study is designed by Gilead, manufacturer of both Truvada and F/TAF. Unlike the H-TEAM’s AMPrEP-study, DISCOVER (also conducted at GGD Amsterdam) studies the effectiveness and safety of the new pill as PrEP.
Half of the participants will get Truvada, the other half will get the new pill F/TAF. Participants nor research staff will know who gets which pill. F/TAF is already available for HIV treatment but its effectiveness as PrEP had not yet been scientifically researched.
Who can sign up for the study?
PrEP is meant as an extra prevention tool for HIV negative people who have a substantial risk for HIV infection. Gay men and other men who have sex with men and transgender women can sign up for DISCOVER on the GGD’s website.
More people choose to buy their generic PrEP abroad or online. Next week you’ll find information on PrEPnu.nl explaining how to do this safely and reliably.Last updated 18/03/2017